Company: BLCO
Filing Date: 2025-10-29
Form Type: 10-Q
Source: 0001860742-25-000023
Chunk: 132

Company: Bausch & Lomb Corp
Filing Date: 2025-10-29
Form: 10-Q
Item: Item 2
Chunk 132
---
ciences, as previously discussed.Acquisition-related contingent consideration in 2025 primarily reflects changes in: (i) the timing of regulatory approval of certain pipeline products and (ii) the estimated amount and timing of projected cash flows of certain products.Operating IncomeOperating income was $1 million and $75 million for the nine months ended September 30, 2025 and 2024, respectively, a decrease in our operating results of $74 million. This decrease primarily reflects the increase in SG&A and R&D, partially offset by the increase in contribution, each as previously discussed.Segment ProfitThe following table presents segment profits, segment profits as a percentage of segment revenues and the period-over-period changes in segment profits for the nine months ended September 30, 2025 and 2024.20252024Change(in millions)AmountPct.AmountPct.AmountPct.Segment Profits / Segment Profit MarginsVision Care$602 28 %$571 28 %$31 5 %Pharmaceuticals124 14 %200 23 %(76)(38)%Surgical3 — %28 5 %(25)(89)%Vision Care Segment ProfitThe Vision Care segment profit was $602 million and $571 million for the nine months ended September 30, 2025 and 2024, respectively, an increase of $31 million. The increase was primarily driven by the increase in revenue, partially offset by higher cost of sales, driven by our contact lens businesses and higher selling expense.

48

Pharmaceuticals Segment ProfitThe Pharmaceuticals segment profit was $124 million and $200 million for the nine months ended September 30, 2025 and 2024, respectively, a decrease of $76 million. The decrease was primarily driven by: (i) higher selling and advertising and promotional expenses related to MIEBO®, (ii) declines in the U.S. generics business, (iii) gross-to-net pricing pressures, primarily attributable to XIIDRA® and MIEBO® and (iv) higher R&D expense.Surgical Segment ProfitThe Surgical segment profit was $3 million and $28 million for the nine months ended September 30, 2025 and 2024, respectively, a decrease of $25 million. The decrease was primarily due to: (i) the overall impact of the voluntary recall of certain enVista IOL products and (ii) higher selling expenses, partially offset by the increase in revenues.Non-Operating Income and ExpenseInterest Expense